People with prostate cancer currently have several treatment options available to them. But one of the oldest, brachytherapy, is losing popularity with physicians. Without action, the skills needed to perform this e ective therapy could be lost.
Brachytherapy uses radioactive material to kill cancerous cells. The conventional approach involves permanently implanting radioactive pellets in and around the prostate. In a newer form of brachytherapy, radioactive material is introduced temporarily through removable catheters. This might improve safety and e icacy, although only limited clinical data are available.
The prostate is a walnutsized gland around the urethra that produces the fluid that carries sperm -semen.
Tumours are most common in men over 65.
Often, first signs are due to pressure on the bladder or urethra.
Radioactive seeds are injected into the prostate and surrounding tissue. The placement of the iodine-125 or palladium-103 seeds is permanent, and cannot be altered after injection.
Dose: Low-energy isotope seeds emit radiation over an extended period.
Facilities: Outpatient procedure with no specialized facilities.
Administration: Permanent implantation means greater care is needed with seed placement.
Evidence: Decades of clinical data support low-dose-rate (LDR) brachytherapy as a stand-alone and adjunct treatment.
Risk potential: Seeds can migrate to other tissues. Sexual partners might be exposed to radiation until the isotope decays.
Dose: High-energy isotopes are applied in multiple, brief sessions.
Facilities: Specialized equipment and a shielded, radiation-safe site.
Administration: Isotope positioning can be adjusted between treatment sessions.
Evidence: Robust comparisons of high-dose-rate (HDR) brachytherapy with other therapies are still needed.
Risk potential:
No radioactive material is left in the body after treatment, reducing the risk of problems later.
Soft catheters
are inserted into a ected areas of the prostate, and radioactive iridium-192 sources are placed in the catheters for each treatment session, which lasts around 2 hours. Multiple treatments are given over 1-2 days in hospital.
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Active surveillance
Many clinicians now opt for careful, regular monitoring, rather than immediate treatment, for people with low-risk, slow-growing tumours.
Low-dose-rate brachytherapy High-dose-rate brachytherapy
Beam therapy
For higher-risk disease, people are typically o ered a more aggressive radiotherapy course, such as external-beam radiation therapy (EBRT).
Radical prostatectomy
The prostate and seminal vesicles, which also secrete fluid found in semen, can be surgically removed to excise the tumour. This type of surgery is often robot-assisted for greater precision.
Hormone therapy
Tumour growth can be stalled by reducing levels of hormones such as testosterone through drugs or surgical castration. 
Cost-e ective
The cost of brachytherapy in US hospitals compares favourably with that of cutting-edge treatments such as advanced forms of beam therapy and robot-assisted surgery 4 . In Europe, treatment costs are more closely matched.
Side-e ect selection
Compared with surgery, brachytherapy tends to carry a lower risk of causing sexual dysfunction and incontinence. But it is associated with greater rates of urinary-tract obstruction than are other treatments 5 .
SLIDE AWAY
Despite its apparent benefits, brachytherapy is struggling to compete with a growing clinical armamentarium. Worldwide, dwindling training opportunities put the future of this technique in jeopardy.
Survival gains
In people with low-risk tumours, brachytherapy is as e ective (96%) as robotic surgery (97%) at preventing cancer recurrence within two years 2 . For high-risk disease, combining brachytherapy with EBRT boosts progression-free survival compared with EBRT alone 3 .
Decreasing use
The proportion of US medical facilities performing brachytherapy has been falling each year since 2007, partly because clinicians are delaying treatment for low-risk malignancies in favour of active surveillance. But brachytherapy's use is also sliding compared EBRT and surgery 6 .
A VALUABLE OPTION
Randomized controlled trials have shown that brachytherapy has similar benefits as those of other treatments, but can be delivered at a lower cost and, in many cases, with more easily managed side e ects.
Funding issues
In the United States, reimbursement rates by health insurer Medicare for brachytherapy (profit for LDR shown) are closer to the true cost than for other, more costly therapies, such as intensity-modulated radiation therapy (IMRT). This means the other therapies are more profitable 7 . In Europe, the reimbursement received by some hospitals doesn't always cover the cost of brachytherapy.
Opportunity cost
As brachytherapy's popularity declines, so do the opportunities for clinicians early in their career to observe and learn the technique. US medical residents increasingly report insu icient opportunity for training in brachytherapy relative to newer therapies 8 . This could lead to further reductions in access. 
